Insights

Gathering insights about Alector…

Similar companies to Alector

Alector Tech Stack

Alector uses 8 technology products and services including Google Analytics, MariaDB, Underscore.js, and more. Explore Alector's tech stack below.

Google Analytics
Analytics
MariaDB
Database
Underscore.js
Javascript Libraries
prettyPhoto
Javascript Libraries
RSS
Miscellaneous
Microsoft Azure
Platform As A Service
HSTS
Security
Coupa
Travel And Expense Management

Media & News

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.
Dec 04, 2024 | www.benzinga.com
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
Nov 27, 2024 | www.zacks.com
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
Nov 26, 2024 | www.benzinga.com
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.
Nov 25, 2024 | www.globenewswire.com
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.
Nov 14, 2024 | www.globenewswire.com
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
Nov 06, 2024 | www.zacks.com
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
Nov 06, 2024 | www.globenewswire.com

Alector's Email Address Formats

Alector uses at least 1 format(s):

Alector Email Formats	Example	Percentage
First.Last@alector.com	John.Doe@alector.com	94%
FL@alector.com	JD@alector.com	4%
FLast@alector.com	JDoe@alector.com	1%
Last.First@alector.com	Doe.John@alector.com	1%

Frequently Asked Questions

Where is Alector's headquarters located?

Alector's main headquarters is located at 131 Oyster Point Blvd Suite 600 South San Francisco, California 94080 US. The company has employees across 5 continents, including North AmericaEuropeAsia.

What is Alector's phone number?

You can contact Alector's main corporate office by phone at

+1-415-231-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Alector's stock symbol?

Alector is a publicly traded company; the company's stock symbol is ALEC.

What is Alector's official website and social media links?

Alector's official website is alector.com and has social profiles on LinkedIn.

How much revenue does Alector generate?

As of December 2024, Alector's annual revenue reached $35M.

What is Alector's SIC code NAICS code?

Alector's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Alector have currently?

As of December 2024, Alector has approximately 268 employees across 5 continents, including North AmericaEuropeAsia. Key team members include Chief Business Officer: N. B.Chief People Officer: C. H. S.Chief Medical Officer: G. R.. Explore Alector's employee directory with LeadIQ.

What industry does Alector belong to?

Alector operates in the Biotechnology Research industry.

What technology does Alector use?

Alector's tech stack includes Google AnalyticsMariaDBUnderscore.jsprettyPhotoRSSMicrosoft AzureHSTSCoupa.

What is Alector's email format?

Alector's email format typically follows the pattern of . Find more Alector email formats with LeadIQ.

How much funding has Alector raised to date?

As of December 2024, Alector has raised $50M in funding. The last funding round occurred on Nov 14, 2024 for $50M.

When was Alector founded?

Alector was founded in 2013.

Alector

Biotechnology ResearchCalifornia, United States201-500 Employees

We have always walked our own path at Alector. That’s what led us to our bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. 

Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. 

Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

Company Overview

Headquarters: 131 Oyster Point Blvd Suite 600 South San Francisco, California 94080 US
Phone number: +1-415-231-****
Website: alector.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: ALEC
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2013
Employees: 201-500

Media & News

Funding & Financials

$50M
Alector has raised a total of $50M of funding over 7 rounds. Their latest funding round was raised on Nov 14, 2024 in the amount of $50M.
$10M$50M
Alector's revenue is in the range of $10M$50M

Funding & Financials

$50M
Alector has raised a total of $50M of funding over 7 rounds. Their latest funding round was raised on Nov 14, 2024 in the amount of $50M.
$10M$50M
Alector's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Alector

Arvinas

Anavex Life Sciences

Athira Pharma

Cytokinetics

Denali Therapeutics

Denovo Biopharma

Sage Therapeutics

Biogen

Celgene

Neurocrine Biosciences

argenx

Alector Tech Stack

Media & News

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector's Email Address Formats

Frequently Asked Questions

Where is Alector's headquarters located?

What is Alector's phone number?

What is Alector's stock symbol?

What is Alector's official website and social media links?

How much revenue does Alector generate?

What is Alector's SIC code NAICS code?

How many employees does Alector have currently?

What industry does Alector belong to?

What technology does Alector use?

What is Alector's email format?

How much funding has Alector raised to date?

When was Alector founded?

Alector

Company Overview

Media & News

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?